Innate Pharma’s (IPHA) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Innate Pharma (NASDAQ:IPHA – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. HC Wainwright currently has a $11.00 price objective on the stock, down from their previous price objective of $11.50. HC Wainwright also issued estimates for Innate Pharma’s FY2029 earnings […]
HC Wainwright reaffirmed their buy rating on shares of Innate Pharma (NASDAQ:IPHA – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. HC Wainwright currently has a $11.00 price objective on the stock, down from their previous price objective of $11.50. HC Wainwright also issued estimates for Innate Pharma’s FY2029 earnings […]
